Search the Newsreel

Enova International (NYSE: ENVA) grants CEO 7,359 stock options with SARs

Enova International's CEO, Steven E. Cunningham, has been granted 7,359 non-qualified stock options paired with limited stock appreciation rights (SARs) at an exercise price of $257.79 per share. These awards will vest in three equal annual installments starting August 5, 2027, and will expire …

Option grant ties Enova International, Inc. (NYSE: ENVA) payout to control-change offer

Enova International granted Chief Strategy Officer Kirk Chartier a non-qualified stock option with a tandem limited stock appreciation right for 2,095 shares. The options have an exercise price of $257.79 per share and vest in one-third increments annually from August 5, 2027 to August …

RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for RenovoRx Inc (RNXT), noting its current earnings forecast score of 8.00 and an average price target of $3.50 based on 4 analysts. It details expected future EPS and revenue figures, and summarizes analyst sentiment as predominantly "Buy".

Enova International (NYSE: ENVA) awards 6,190 stock options to Executive Chairman

Enova International (NYSE: ENVA) has granted its Executive Chairman, David Fisher, 6,190 non-qualified stock options. These options, with an exercise price of $257.79 per share and an expiration date of August 5, 2033, vest in three equal annual installments beginning August 5, 2027, contingent …

Enova International (NYSE: ENVA) awards 1,500 options to CFO Scott

Enova International (NYSE: ENVA) has granted its CFO, Cornelis Scott, 1,500 non-qualified stock options with a limited stock appreciation right. These options have an exercise price of $257.79 per share, expire on August 5, 2033, and vest in three equal increments on August 5, …

RenovoRx Inc (RNXT) Stock News Today

Enovis Corporation Stock 12‑Month Price Target Cut to $41.25, Implies 37% Upside

The average 12-month price target for Enovis Corporation (ENOV) stock has been lowered from $41.58 to $41.25 by analysts, despite this reduction, the new target still suggests a potential upside of approximately 37% based on the August 5th closing price. The consensus rating for …

Cenovus Energy (TSE:CVE) Shares Cross Above 200-Day Moving Average - Time to Sell?

Cenovus Energy (TSE:CVE) shares recently crossed above their 200-day moving average, signaling improved technical momentum. The company reported strong quarterly earnings and increased its dividend, yet insiders have sold a significant number of shares. Analysts maintain a bullish outlook with an average "Buy" rating …

Enovis Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:ENOV) 2026-08-07

Enovis earnings beat by $0.05, revenue topped estimates

Enovis Q2 2026 presentation shows margin gains, stock falls 9%

Enovis Q2 2026 slides show margin gains despite stock decline

Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The …

Enovis reaffirms 2026 outlook and targets >25% free cash flow conversion as Arvis rollout expands

Earnings Call Insights: Enovis (ENOV) Q2 2026 MANAGEMENT VIEW * CEO Damien McDonald said Q2 results showed “the strength and stability of our diversified product portfolio” and reported “organic growth of 5%, driven by 6% organic growth in Recon and 3% organic growth in …

Cenovus Energy (TSX:CVE) Lifts Guidance Following Strong Results With Valuation Back In Focus

Cenovus Energy recently reported strong second-quarter 2026 results, showing higher sales, net income, and upstream production, alongside updated guidance and capital returns through dividends and share buybacks. Despite a significant year-to-date share price increase of 64.70% and a five-year return of 326.13%, the company …

Enovis Backs 2026 Guidance >ENOV

Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.

RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com

RenovoRx Inc. announced that its RenovoCath drug-delivery device was used commercially for the first time to treat a sarcoma patient at CARTI Cancer Center. This marks an expansion beyond the company's prior focus on pancreatic cancer, demonstrating the device's potential for local chemotherapy delivery …

Earnings call transcript: Enovis tops Q2 2026 EPS view but shares fall 6.7%

Why Enovis (ENOV) Shares Are Sliding Today

Enovis Corporation's shares fell 12.8% after reporting second-quarter earnings, despite revenue and adjusted earnings surpassing Wall Street expectations. The decline was attributed to a weaker full-year earnings per share outlook and a significant contraction in the company's adjusted operating margin, which fell 6.7 percentage …

Enovis CORP 2026: Revenue $582.78M, EPS ($0.02) — 10-Q Summary

Enovis CORP (ENOV) reported its 2026 Q3 results, showing a revenue of $582.78M, a 3.2% increase year-over-year. The company significantly reduced its net loss to ($1.19M) from ($36.74M) in the prior-year quarter, with diluted EPS improving to ($0.02) from ($0.64). This performance was driven …

Cenovus Energy Inc. stock rises Thursday, outperforms market

Cenovus Energy Inc. (CVE) saw its stock rally by 2.04% to C$39.61 on Thursday, outperforming the broader Canadian market. The S&P/TSX Composite Index fell by 0.03%, while Cenovus Energy Inc. closed 10.2% below its 52-week high.

Enovis (NYSE:ENOV) Posts Q2 CY2026 Sales In Line With Estimates

Enovis (NYSE:ENOV) reported Q2 CY2026 sales of $582.8 million, meeting Wall Street estimates, with non-GAAP profit exceeding consensus by 6.3% at $0.90 per share. The company reaffirmed its full-year revenue and Adjusted EPS guidance. While long-term revenue growth has been a challenge, recent two-year …

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx, Inc. announced the first commercial clinical use of its FDA-cleared RenovoCath device for drug delivery in treating a sarcoma patient at the CARTI Cancer Center. This milestone demonstrates the potential for RenovoCath to expand beyond pancreatic cancer to other solid tumors for localized …

A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath

RenovoRx (Nasdaq: RNXT) announced the first commercial clinical use of its RenovoCath device for localized chemotherapy delivery in a sarcoma patient at CARTI Cancer Center. This marks an expansion of the device's application beyond pancreatic cancer, demonstrating its potential for treating other solid tumors …

Enovis posts Q2 2026 revenue $583M, adjusted EBITDA $104M and reaffirmed full-year guidance

Enovis reported Q2 2026 net sales of $582.8 million and adjusted EBITDA of $104.3 million, showing growth in both reported and organic sales. The company reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion. Management highlighted improved …

Form 8K Enovis Corp For: 6 August By Investing.com

This article reports on the filing of Form 8K by Enovis Corp on August 6th. The brief news item includes standard financial market data, indices, commodities, and various stock performances. It also highlights popular news articles from Investing.com and Reuters on topics ranging from …

Enovis Q2 2026 earnings: Reconstructive growth lifts margins

Enovis (NYSE: ENOV) reported strong Q2 2026 results, with net sales up 3.2% to $582.8 million and GAAP diluted EPS improving significantly. Reconstructive was the primary sales driver, and the company achieved improved operating leverage, leading to a GAAP operating profit. Enovis reaffirmed its …

Enovis Announces Second Quarter 2026 Results

Enovis Corporation announced its financial results for the second quarter ended July 3, 2026, reporting sales growth of 3% on a reported basis and 5% organically, reaching $583 million. The company experienced an 8% reported growth in Reconstructive sales, alongside a net loss of …

Enova Mining Ltd (ASX: ENV) Reports Further Rare Earth Results from East Salinas Regional Drilling Program

Enova Mining Announces Additional Auger Drilling Assay Results from East Salinas Regional REE Exploration

Earnings Flash (ENOV) Enovis Corporation Reports Q2 Revenue $582.8M, vs. FactSet Est of $581.8M

Enovis Corporation (ENOV) announced its Q2 revenue of $582.8 million, surpassing FactSet's estimate of $581.8 million. The company also reported Q2 adjusted EPS of $0.90 per share, exceeding the FactSet estimate of $0.85 per share, and reaffirmed its earnings guidance for the year 2026.

Enova Mining expands rare earth footprint at Brazil’s East Salinas project

Enovis earnings up next as analysts eye Lima deal, cash flow

Enovis Corp. is preparing to report its second-quarter earnings, with analysts focusing on the company's Lima integration and cash flow generation amidst tempered expectations. Despite a sequential decline forecasted from Q1, Wall Street maintains a bullish outlook with a consensus "buy" rating. Investors will …

Zacks.com featured highlights Enova, PBF, Huron , and The Cheesecake

Zacks.com highlights five stocks with strong relative price strength that investors should consider: Enova International (ENVA), Invesco Ltd. (IVZ), PBF Energy (PBF), Huron Consulting Group Inc. (HURN), and The Cheesecake Factory Inc. (CAKE). These companies are identified based on their consistent outperformance of the …

RenovoRx to Present TAMP Platform, TIGeR-PaC Trial Update at JonesTrading Webinar Aug 13

RenovoRx will present its TAMP platform and provide an update on the TIGeR-PaC trial at a JonesTrading webinar on August 13. CEO Shaun Bagai and oncology KOLs will discuss the RenovoCath and the company's commercial progress, including sales figures and growth plans. The webinar …

Top Penny Stocks to Watch: Why Is eNova Mining (ASX:ENV) in Focus?

Enova International (ENVA) Earnings Strength Puts Valuation Back In Focus